As of November 7, 2026, Pasithea Therapeutics Corp. is a publicly traded company (Nasdaq: KTTA); its largest reported holder is Coastlands Capital LP, with 11.48% on Schedule 13G/A of July 1, 2026, then Vivo Opportunity Fund Holdings, L.P. (9.99%) (Schedule 13G/A, July 1, 2026).
Is this your company?
About to sign with, pay or invest in Pasithea Therapeutics Corp.? See the free Snapshot first.
Free to see. No signup.
Is Pasithea Therapeutics Corp. a real, registered company?
- Pasithea Therapeutics Corp. files with the SEC under CIK 1841330 (its SEC filings).
- Its shares are listed under the ticker KTTA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Miami Beach, Florida, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Pasithea Therapeutics Corp. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Vivo Opportunity Fund Holdings, L.P. (filed 2026-08-14).
Who are Pasithea Therapeutics Corp.'s owners and officers?
Pasithea Therapeutics Corp.: incorporated in Delaware; business address in Miami Beach, Florida; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-06 | Opaleye Management Inc. | 0% |
| Schedule 13G/A, 2026-08-14 | Vivo Opportunity Fund Holdings, L.P. | 9.99% |
| Schedule 13G/A, 2026-07-31 | Opaleye Management Inc. | 6.14% |
| Schedule 13G/A, 2026-07-01 | Coastlands Capital LP | 11.48% |
| Schedule 13G, 2026-06-23 | Stonepine Capital Management, LLC | 5.8% |
| Schedule 13G/A, 2026-05-15 | Ameriprise Financial, Inc. | 5.4% |
| Schedule 13G, 2026-04-22 | Funicular Funds, LP | 7.4% |
| Schedule 13G, 2026-04-08 | Opaleye Management Inc. | 9.99% |
| Schedule 13G, 2026-02-27 | Coastlands Capital LP | 9.99% |
| Schedule 13G/A, 2026-02-17 | Squadron Master Fund LP | 9.9% |
| Schedule 13G, 2026-02-17 | Ameriprise Financial, Inc. | 8.4% |
| Schedule 13G/A, 2026-02-17 | Cvi Investments, Inc. | 3.8% |
Questions about who owns Pasithea Therapeutics Corp.
Who owns Pasithea Therapeutics Corp.?
On this page, 6 holders' latest ownership filings report 5% or more of Pasithea Therapeutics Corp.: Coastlands Capital LP (11.48%, Schedule 13G/A, filed 2026-07-01), Vivo Opportunity Fund Holdings, L.P. (9.99%, Schedule 13G/A, filed 2026-08-14), Squadron Master Fund LP (9.9%, Schedule 13G/A, filed 2026-02-17), Funicular Funds, LP (7.4%, Schedule 13G, filed 2026-04-22) and Stonepine Capital Management, LLC (5.8%, Schedule 13G, filed 2026-06-23); 1 more is listed above.
Who are the largest shareholders of Pasithea Therapeutics Corp.?
By the share each holder's latest filing reports, the largest holders of Pasithea Therapeutics Corp. on this page are Coastlands Capital LP (11.48%), Vivo Opportunity Fund Holdings, L.P. (9.99%) and Squadron Master Fund LP (9.9%).
When did Coastlands Capital LP buy into Pasithea Therapeutics Corp.?
The filings give report dates, not purchase dates. The earliest filing from Coastlands Capital LP on this page is the Schedule 13G, filed 2026-02-27, reporting 9.99%; its latest, Schedule 13G/A filed 2026-07-01, reports 11.48%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Pasithea Therapeutics Corp.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Pasithea Therapeutics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pasithea Therapeutics Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
23 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Pasithea Therapeutics Corp. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Coastlands Capital LP, a 10% owner: 3,835,035 shares (11.5% of shares outstanding), held indirectly through By Coastlands Capital LP (Form 4, 2026-06-22).
- , a director: 199,691 shares (0.60% of shares outstanding) (Form 4, 2025-12-01).
- , the chief executive and a director: 73,334 shares (0.22% of shares outstanding) (Form 4, 2025-12-01).
- , a director: 35,833 shares (0.11% of shares outstanding) (Form 4, 2025-12-01).
- , a director: 33,333 shares (0.10% of shares outstanding) (Form 4, 2025-12-01).
Shares outstanding: 33,414,448 as of 2026-08-12, from the company's latest SEC cover page.
How much has Pasithea Therapeutics Corp. raised?
Latest IPO step: Pasithea Therapeutics Corp. filed its final IPO prospectus, ticker KTTA (424B4, 2025-12-01).
IPO filings: 424B4, 2025-12-01, S-1/A, 2025-11-26, S-1, 2025-11-18, 424B4, 2025-05-07, S-1, 2025-05-01; ticker KTTA on Nasdaq Capital Market.
Keep reading
More on Pasithea Therapeutics Corp. and the records around it.
Pasithea Therapeutics Corp. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Funicular Funds, LP also filed stake reports on 10 other companies: AmpliTech Group, Inc. (Oct 2026), SYNLOGIC, INC. (Jul 2026), Rein Therapeutics, Inc. (May 2026)
- Opaleye Management Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Q32 Bio Inc. (Nov 2026)
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/pasithea-therapeutics